Citius pharmaceuticals executes definitive agreement to merge wholly owned subsidiary with tenx keane acquisition to form publicly listed citius oncology, inc.

Citius pharmaceuticals, inc. to receive $675 million in equity of citius oncology, inc. and retain approximately 90% majority control in publicly listed citius oncology, inc. post transaction transaction anticipated to close in the first half of 2024 cranford, n.j. and new york , oct. 24, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius pharma" or the "company") (nasdaq: ctxr), a biopharmaceutical company developing and commercializing first-in-class critical care products, and tenx keane acquisition ("tenx") (nasdaq: tenku), a publicly traded special purpose acquisition company (spac), today announced that they have entered into a definitive agreement, dated october 23, 2023, for a proposed merger of tenx and citius pharma's wholly owned oncology subsidiary that will continue as a public company listed on the nasdaq exchange.
CTXR Ratings Summary
CTXR Quant Ranking